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Abstract 
Diagnostic cardiac catheterizations are pre-
dominantly  performed  using  the  femoral
artery  access.  Several  devices  have  been
developed to aid in the closure of femoral arte-
riotomy. 
Safeguard® is a new pneumatic compres-
sion device that has been developed for com-
pression of the femoral artery after brief man-
ual compression. We hereby report the case of
an elderly patient who underwent a percuta-
neous coronary intervention via the femoral
artery  in  whom  a  Safeguard™  device,  left
overnight because of persistent oozing, pro-
voked an extensive pressure ulcer. Knowledge
of this potential complication is important to
minimize its occurance and provide appropri-
ate treatment.
Introduction
The femoral approach is still the most com-
monly  used  route  for  diagnostic  cardiac
catheterizations  and  percutaneous  coronary
interventions. At the end of the procedure the
femoral artery is usually compressed manually
to  control  bleeding  until  hemostasis  is
achieved. Local vascular complications such as
bleeding and hematoma are not uncommon,
ranging from less than 1% to  12%.1,2
Many devices have been developed to aid in
the closure of the femoral arteriotomy, includ-
ing the VasoSeal® (Datascope Inc., Montvale,
NJ,  USA),  AngioSeal® (St.  Jude  Medical
Devices,  Minneapolis,  MN,  USA),  the
Starclose® clip  closure  system  (Abbott
Vascular,  Redwood  City,  CA,  USA),  and  the
Perclose® (Perclose, Redwood City, CA, USA)
suture-mediated closure system. In two recent
meta-analyses3,4 these  devices  have  proven
their efficacy in significantly reducing time to
hemostasis  while  simultaneously  improving
patient comfort. 
Vascular closure devices should be avoided
or  used  with  caution  with  non-common
femoral artery sheath location, small femoral
artery size, bleeding diathesis, morbid obesity,
inflammatory disease, uncontrolled hyperten-
sion and in the presence of significant periph-
eral vascular disease, especially with calcifica-
tion.
In an attempt to reduce local complications,
inflatable  compression  devices  such  as  the
FemoStop® (RADI  Medical  System  AB,
Uppsala,  Sweden)  and  the  Safeguard®
(Datascope Corp., Fairfield, NJ, USA) (Figure
1) have thus been developed for compression
of the femoral artery and are now in use in
some centers because they are well accepted
by the nursing staff. 
We  hereby  report  a  clinical  experience
describing  a  significant  complication  occur-
ring after Safeguard® use for femoral hemo-
stasis.  In  this  case,  an  extensive  pressure
ulcer developed in the groin of a very elderly
patient  in  whom  a  Safeguard® had  been
applied overnight because of persistent oozing
after diagnostic coronary angiography.
Case Report
A 95-year old diabetic female was referred
to our catheterization laboratory for workup
of  percutaneous  aortic  valve  replacement
because of a severe calcified aortic stenosis
and pronounced dyspnea on effort. The diag-
nostic angiogram was performed via the right
femoral artery. The patient was anesthetized
locally  with  2%  lidocaine  and  the  femoral
artery cannulation and placement of a 6 Fr
introducer sheath (Cordis, Miami, FL, USA)
were performed by the usual technique with-
out  complications.  Angiography  disclosed  a
significant stenosis of the mid tract of the
right coronary artery which was treated with
a 3.5¥18 mm bare metal stent dilated at up to
20 ATM, achieving a good final angiographic
and clinical result. 
Three hours after the procedure, when a
check of the activating clotting time showed
a value of 150 sec, the sheath was removed
and  manual  compression  was  performed.
After  achieving  hemostasis,  a  24  cm
Safeguard® pressure  assisted  device  was
positioned in the point of maximum femoral
pulse and inflated with 40 ml of air, as recom-
mended  in  the  device  package  insert.  No
bleeding or oozing was found after manual
compression or shortly after positioning the
Safeguard®. 
Two  hours  later  the  Safeguard® bulb  was
deflated but a persistent oozing was observed. It
was, therefore, reinflated with 20 mL. Similarly,
4 h after positioning the Safeguard® another
deflation  attempt  was  performed,  but  oozing
was  still  present  and  the  device  was  again
inflated with 20 mL of air, and kept overnight.
Since the volume of inflated air was signifi-
cantly lower than recommended, the nurse did
not deflate the bulb every 2 h as suggested by
the Safeguard instructions. In the early morn-
ing of the following day, the device could be
removed  without  any  evidence  of  oozing  or
bleeding. Nonetheless, a circular area of non-
blanchable  erythema  was  observed  which
developed into a pressure ulceration two days
after (Figure 2), with partial-thickness loss of
dermis. The lesion was treated with frequent
irrigations  of  saline  solution,  gentle  manual
debridement and hydrocolloid-based dressings
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(3M  TegaSorb®,  Minneapolis,  MN,  USA)  and
resolved without any need for systemic antibi-
otics in a week, leaving, however, a minor scar.
Discussion
The  24  cm  Safeguard® pressure-assisted
device  is  a  disposable  device  with  a  clear
polyurethane  bladder  and  a  pressure  sensi-
tive self-adhesive peel backing. A luer valve
enables  a  syringe  to  be  connected  to  the
device in order to inflate the central bladder
with air to provide pressure to the puncture
site. Adverse effects reported by the manufac-
turer  that  may  result  from  the  use  of  this
device  include  hematoma,  local  bleeding,
pseudoa  naurysm  and  arterio-venous  fistula;
all complications associated with bleeding.
To date, only a single prospective, non-ran-
domized,  multicenter  study5 has  been  con-
ducted in 101 low-risk patients to evaluate the
safety  and  effectiveness  of  the  Safeguard®
space.  The  device  proved  to  be  effective  in
reducing  active  compression  time  without
increasing risk in patients undergoing diag-
nostic and interventional procedures. 
The case report described here highlights
how  such  a  device,  despite  its  inherently
favorable features including user friendliness
for staff, may seriously harm a patient if the
instructions for use are not meticulously fol-
lowed.
Given  its  inherent  mechanical  pressure
properties,  it  is  absolutely  mandatory  to
deflate the bulb of the device every 2 hours to
allow  for  capillary  refill  in  accordance  with
the  device  instructions.    Even  if  long-term
harm  to  the  patient  could  be  avoided,  thus
leading to an acceptable final cosmetic result,
greater harm could have been caused, possi-
bly with potentially dire medico-legal implica-
tions (e.g. in the case of groin skin damage in
a younger woman).
Conclusion
Vascular access complications are amongst
the most common adverse events associated
with coronary angiography and intervention.
A number of devices are available to aid in
achieving  post-procedure  homeostasis.
Information on vascular complications from
access of the femoral artery, the methods of
arterial  closure,  and  post-procedural  care
instructions (including avoidance of lenghty
mechanical  pressure  with  pneumatic
devices) can help physicians and nurses to
provide  safe  and  effective  care  to  patients
after cardiac catheterization. 
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Figure 1. The Safeguard® 24 cm pressure
assisted dressing.
Figure 2. Right groin’s extensive (12¥9 cm)
pressure ulcer with loss of epidermis and
dermis.